2013 Focus for Biogen Investors

Before you go, we thought you'd like these...
Before you go close icon

Disappointment struck Biogen  -- one of the best performing big biotech stocks of 2012 -- yesterday after the company announced that its experimental ALS drug failed its phase 3 clinical trial. This is sad news for ALS patients, but multiple sclerosis patients and Biogen investors are now looking toward the potential approval from the Food and Drug Administration for the company's drug BG-12. In this video, our analysts discuss the recent news and also give an overview of Biogen's potential position in the MS drug market.

Considering that shares of Biogen climbed 30% in the last 12 months, investors can certainly make incredible gains with health care stocks, but this is also one of the market's riskiest sectors. Motley Fool co-founder David Gardner's picks, which range across many sectors, have frequently trounced the market.


How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article 2013 Focus for Biogen Investors originally appeared on Fool.com.

Brenton FlynnMax Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners